CADx - Radiomics to Distinguish the Origin of Ovarian Tumors
NCT ID: NCT05174377
Last Updated: 2022-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
600 participants
OBSERVATIONAL
2021-04-05
2025-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective: To improve accuracy for distinguishing benign from malignant disease in patients presenting with an ovarian mass by using a computer aided detection algorithm.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ovarian Cancer Radiomics Approach in CT Led Evaluation
NCT06817174
Imaging Study in Advanced Ovarian Cancer
NCT03808792
Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer
NCT04971421
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195
Clinical Impact of Dedicated MR Staging of Ovarian Cancer
NCT03399344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Artificial Intelligence (AI) for radiology is currently being developed by the Eindhoven University of Technology (TU/e) and Philips Research Europe and may provide a potential solution to this problem.
The currently developed algorithm (CADx), using a support vector machine (SVM), showed within a small population of about 100 patients a sensitivity of 74% and specificity of 74%. These are promising results to train this algorithm even further with more CT-scans images and the addition of clinical variables and even liquid biopsies.
Type of study: Retrospective study cohort This is a retrospective analysis on known data in which definitive patients diagnosis has already been established and current analysis will not affect treatment plan.
No products for patients are used, only computer aided diagnosis is used on existing radiological imaging, namely CT-scans.
This study is linked to two other Dutch trials in which ovarian tumor biomarkers are assessed in order to find out the origin of ovarian tumors preoperatively.
The first is the HE4-prediction study, with local protocol ID NL58253.031.16. The second is the OVI-DETECT study, with clinicaltrial.gov number NCT04971421.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT-scan algorithm
CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* underwent surgery
* histological proof of tumor
Exclusion Criteria
* lack of correct description of staging in OR report when applicable
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Netherlands Cancer Institute
OTHER
Eindhoven University of Technology
OTHER
Amsterdam UMC, location VUmc
OTHER
Leiden University Medical Center
OTHER
Amphia Hospital
OTHER
Gynaecologisch Oncologisch Centrum Zuid
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jurgen M.J. Piek
MD-PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catharina hospital
Eindhoven, North Brabant, Netherlands
Netherlands Cancer Institute
Amsterdam, North Holland, Netherlands
Leiden University Medical Center
Leiden, North Holland, Netherlands
Amsterdam medical center
Amsterdam, , Netherlands
Amphia hospital
Breda, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
OVI-DETECT study link at clinicaltrial.gov
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RADIOMICS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.